Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled: PRESS AND THIRD PARTY COVERAGE: 08/08/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 319
Posts 41,017
Boards Moderated 30
Alias Born 09/20/01
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
XenaLives Member Level  Thursday, 08/08/19 06:24:46 AM
Re: None
Post # of 237982 
Compiled: PRESS AND THIRD PARTY COVERAGE: 08/08/19
______________________________________________________________________________________

Mayo Clinic researcher states that the P2a improved cognition and function:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149549864

S&P Global Market Intelligence, quoting Dr. Missling:
Failures in Alzheimer's research spur new approaches to drug development
Discussion follows:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149043113

Experimental pill shows promising results for Parkinson's
https://pressfrom.info/au/lifestyle/health/-121247-experimental-pill-shows-promising-results-for-parkinson-s.html

NEWS!!! March 4, 2019 Third party paper on cellular recycling.
https://www.anavex.com/anavex-life-sciences-reports-publication-of-new-data-that-show-anavex2-73-induces-cellular-recycling-process-linked-to-the-prevention-and-treatment-of-age-associated-diseases/

access to above paper
https://www.mdpi.com/2073-4409/8/3/211/htm

What is proteostasis?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147258047

This MOA applies to the aging process in general:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147257995

There is a complete section on autophagy in the MOA and Medical compiled post

Anavex 2-73 and a Nobel Prize winner (from georgejjl)


Richard Engel on his son with Rett Syndrome:
https://www.today.com/parents/rett-syndrome-richard-engel-son-henry-s-milestone-life-special-t150348
A January 2018 article by Engel talks about how his son's genes are being used for research
https://www.today.com/parents/rett-syndrome-richard-engel-shares-his-son-s-rare-condition-t121886

Videos of Australian Patients from the P2a trial





Pauline Stevens the Pianist.
https://www.geelongadvertiser.com.au/news/steve-macfarlane-explains-the-alzheimers-worldfirst-drug-trial-at-caulfield-hospital/video/03fe27ae89bdce4912cabf865a99ed80

Extended P2a participant regains driver's license:

https://www.australianageingagenda.com.au/2018/07/13/next-stage-of-national-drug-trial-underway/

Thanks to polarbear for this link.. all I can say is "It's about time"...
https://alzheimersnewstoday.com/2018/10/31/anavex-2-73-slows-cognitive-decline-alzheimers-extension-study/

CA governor's task force

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146900633

Press coverage of AVXL at 2018 CTAD:
http://cnafinance.com/anavex-life-sciences-avxl-stock-gaining-on-clinical-data/20696
http://www.bioworld.com/content/tiny-anavex-thinks-big-three-year-ad-data-ctad

Recent press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:

https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73

Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822

Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results

When the hugs and kisses stopped...
https://www.abc.net.au/news/2018-11-14/dementia-onset-when-the-hugs-stopped/10433574

UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909





In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist